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of psoriasis. Methods: A systematic literature search was conducted and studies 
were identified from PubMed and conference proceedings. Studies published in 
English language between January 2001 and May 2013, and reporting direct and 
indirect economic burden of psoriasis were identified using search strategies. A 
total of 1,181 abstracts were screened by two researchers; any discrepancy was 
resolved by a third researcher. Results: Forty studies (34 primary articles and 6 
conference abstracts) from 12 countries including 19 from the US, 4 from Canada, 3 
from Germany, 2 each from Italy, The Netherlands and the UK, 1 each from Australia, 
Brazil, Israel, Spain, Sweden and Switzerland, and 2 multinational studies met the 
inclusion criteria. Overall, 27 studies assessed direct costs, 3 studies assessed 
indirect costs, and 10 studies evaluated both. Major contributors of direct costs 
included medication costs, office visits, hospitalization costs and monitoring costs. 
Productivity loss, patient and caregiver work days lost, and restricted activity days 
were key drivers of indirect costs. Among the European countries, the most recent 
studies reported an annual total cost (direct and indirect cost) per patient of € 11,928 
in Sweden, € 8,372 in Italy, and € 2,866 - € 6,707 in Germany based on treatment type. 
In US and Canada, the annual direct and indirect economic burden of psoriasis was 
$1.4 billion and CDN$1.7 billion respectively. ConClusions: Costs associated with 
chronic plaque psoriasis are high in many countries indicating a continued need 
for new treatments.
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objeCtives: To identify the real world standard of care, treatment patterns, medi-
cal history, resource use and costs of patients with choroidal neovascularization 
(CNV) secondary to pathologic myopia (PM) in Canada. Methods: With enroll-
ment still ongoing, 85 patients with Myopic CNV were recruited by ophthalmolo-
gists and retina specialists from 16 centres across Canada to participate in this 
retrospective, multicenter study. Medical records covering at least one year of fol-
low up data from the CNV diagnosis, and up to two years, were analyzed to gather 
all information related to Myopic CNV. Results: Data from 67 study participants 
was analyzed. Patients had a mean age of 55.4 years (range: 27 – 80 years) at the 
time of their PM diagnosis (CNV affected eye), and 56.0 years (range: 29 - 82 years) 
at the time of their first lifetime CNV episode. The analysis showed that 71.6% 
of participants were female, 71.6% were Caucasian, 61.2% had subfoveal CNV in 
the affected eye and 31.3% had more than one lifetime CNV episode reported. 
Based on their visual acuity at the time of CNV diagnosis at the beginning of the 
chart review period, they were grouped by the Snellen score of the affected eye 
into 7 groups: 20/32-20/20 (n= 5), 20/50-20/32 (n= 5), 20/80-20/50 (n= 15), 20/125-
20/80 (n= 12), 20/200-20/125 (n= 2), 20/320-20/200 (n= 7) and < = 20/320 (n= 21). The 
approximate mean Snellen score was 20/160 in the affected eye and 20/63 in the 
fellow eye. The proportion of patients that had both eyes affected with PM was 
58.2%. ConClusions: Information on Myopic CNV is very limited in the literature. 
The baseline characteristics of Canadian patients presented here are aligned with 
other few data available in the public domain. This is the first study worldwide 
investigating the burden of Myopic CNV and the final results, will help us better 
understand this debilitating disease.
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objeCtives: Retinal vein occlusion (RVO) is the most common retinal vascular dis-
order with the potential for significant vision-related morbidity. The societal costs 
associated with CRVO are little known. Only a few studies reports on the burden of 
retinal vein occlusion or the resource use and cost of Central Retinal Vein Occlusion 
(CRVO). No specific burden of illness study is available that describes the situation in 
France. The purpose of the current study was to create a model that enables study of 
the societal costs of CRVO in France. The perspective of the model was prepared from 
a societal perspective. Methods: The input for health care utilisation input, were 
derived from a client survey conducted among French clinical experts in ophthal-
mology. An incidence-based model was constructed, which included the following 
parameters: direct and indirect costs, including treatment with drugs, non-drug 
treatments (e.g., grid laser photocoagulation and pan retinal photocoagulation), 
monitoring of the disease, adverse events, lost productivity, transportation and the 
cost of blindness. Results: In France the incidence of people suffering from CRVO 
was estimated to 10,471 (2011). The average annual contribution from each patient 
to the overall cost of CRVO was calculated to 11,434€ . The yearly direct and indirect 
costs were estimated to app. 120mill Euros. The contributing factors driving the 
cost of CRVO, in France, are, cost of blindness 29%, drug treatment cost 26%, cost of 
adverse events 25% and cost from monitoring 14%. ConClusions: Despite CRVO 
being a uncommon disease, the annual costs to the French society, based on the 
incidence of CRVO, are substantial. The cost of blindness account for 26% of the 
total annual costs indicating that there is a potential for reducing those costs with 
improved treatment options in CRVO.
PSS18
CoStS of BeSt SuPPortive Care in the treatMent of Moderate-to-
Severe PSoriaSiS in the united StateS
Tencer T., Li S., Zhang F.
Celgene Corporation, Summit, NJ, USA
objeCtives: To describe the best supportive care costs of psoriasis patients follow-
ing discontinuation of conventional systemic or biologic therapy. Methods: Adult 
patients with ≥ 2 psoriasis diagnoses (from office visits) with continuous insurance 
5-dimension National Eye Institute Refractive Error Quality of Life (NEI-RQL)-42 
scale; expenditure on spectacles was also measured. Results: The proportion of 
patients with a postoperative improvement in visual acuity of 0.1 logMAR or better 
was significantly higher with the multifocal IOL than with monofocal lenses (45.7% 
vs. 2.1%, respectively; P< 0.0001), as was the proportion of patients achieving spec-
tacle independence (73.3% vs. 25.3%, P< 0.0001). At 6 months, the group difference 
in NEI-RQL-42 scores for dependence on correction significantly favoured the mul-
tifocal IOL (mean difference 37.3, 95% confidence interval 28.7–46.0, P< 0.0001), but 
there were no significant differences between the groups in scores for the other four 
dimensions (near vision, appearance, limitation in activity, and satisfaction with 
correction). The mean costs of spectacles in patients with multifocal or monofocal 
IOLs were € 154.42 and € 267.21, respectively, for lenses and € 66.59 and € 74.35, respec-
tively, for frames. ConClusions: Compared with monofocal IOLs, the multifocal 
IOL resulted in greater spectacle independence and lower expenditure on glasses. 
These findings are consistent with those of a previous economic modelling study, 
which showed that the use of this lens resulted in significant cost savings due to a 
reduced need for spectacles.
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objeCtives: The aim was to analyze the total direct costs of treatment of cutane-
ous drug reactions (CDR) from health care provider and public payer perspective 
divided by diagnosis groups. Methods: We analyzed retrospectively data from 
164 patients (57 men, 107 women) hospitalized in the Department of Dermatology, 
Military Medical Institute in Warsaw (from 2002 to 2012) due to CDR. Total direct 
costs from the public payer and health care provider were calculated for different 
diagnoses (based on ICD 10 codes). The analysis was based on data derived from 
the patients’ medical charts, daily medication logs, and cost data provided by the 
hospital organization and accounting department. The services paid by National 
Health Fund (NHF) were grouped based on ICD-10 and DRG system. For the pur-
pose of the analysis the hospitalization costs were calculated based on the prices 
for medical services established by the NHF on the basis of a contract with the 
selected health institution. Results: In the study group 3 CDR groups were iden-
tified: J38-severe skin disease (generalized rash) J39-large dermatological diseases 
(erythema multiforme) J49-gentle dermatological diseases (urticaria). From NHF 
perspective the most expensive procedure is J 38 – 962 € per patient (1€ = 4.24 PLN), 
the lower cost is for J39 and J 49 (476€ and 331€ respectively). From health care 
provider’s perspective the total direct costs equal: J38 – 630 € , J 39 – 552 € , J49 – 375€ . 
Differences in costs could be due to high costs of the clinically severe diseases treat-
ment incurred by the provider while according to the NHF, these units are classified 
as large dermatological diseases and thereby direct treatment costs are much lower 
than real provider’s costs. ConClusions: The analysis results suggest taking into 
consideration reclassification of the services by NHF or better estimation of DRG 
groups by the public payer.
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objeCtives: The societal costs associated with CRVO are little known. Only a few 
studies report on the burden of retinal vein occlusion, the resource use and cost of 
CRVO. No specific burden of illness study is available that describes the situation in 
the UK. The purpose of this study was to create a model that enabled the calcula-
tion of the societal costs of CRVO in the UK. Methods: The health care utilisation 
inputs for the model were derived from a survey conducted among UK ophthalmol-
ogy experts. The model included parameters that contribute to the costs of illness 
of CRVO and is based on the prevalence of CRVO in the UK. These were direct and 
indirect costs including drug treatment, non-drug treatment (e.g. grid laser photo-
coagulation and pan retinal photocoagulation), monitoring of the disease, adverse 
events, lost productivity, transportation and the cost of blindness. Results: In 
the UK, the average annual contribution from each patient to the overall cost of 
CRVO was calculated to £14,692. The annual cost for the UK society was estimated 
to be almost £700 million. The main part of the cost, 42%, was from monitoring of 
the disease. Also, 20% was from the cost of blindness, 16% from the drug treatment 
and 15% from treatment of adverse events. ConClusions: Despite CRVO being an 
uncommon disease, the annual costs to the UK society are substantial. The total 
burden of CRVO is most sensitive to changes in the cost associated with interven-
tions, with the number of hospital visits, ophthalmoscopy examinations and the 
number of optical coherence tomography (OCT) procedures as the dominating fac-
tors. By reducing the cost and/or the number of interventions by 25%, the overall 
burden of CRVO decreases from £14,692 to £13,147 per patient, which corresponds 
to a societal saving of almost £73 million per year.
PSS15
SySteMatiC literature review of eConoMiC Burden of ChroniC 
Plaque PSoriaSiS
Feldman S.R.1, Burudpakdee C.2, Gala S.2, Mallya U.3
1Wake Forest University, Winston-Salem, NC, USA, 2MKTXS, Raritan, NJ, USA, 3Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA
objeCtives: Psoriasis is a significant economic burden to both patients and pay-
ers in terms of direct and indirect costs. Previous systematic reviews have been 
limited with regards to geographical region of assessment and type of economic 
outcomes reported. Hence, the objective of this systematic review is to provide a 
global comprehensive understanding of the direct and indirect economic burden 
